These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37580082)

  • 21. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cysteamine Protects Neurons from Mutant Huntingtin Toxicity.
    Arbez N; Roby E; Akimov S; Eddings C; Ren M; Wang X; Ross CA
    J Huntingtons Dis; 2019; 8(2):129-143. PubMed ID: 30856117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin-like growth factor 2 (IGF2) protects against Huntington's disease through the extracellular disposal of protein aggregates.
    García-Huerta P; Troncoso-Escudero P; Wu D; Thiruvalluvan A; Cisternas-Olmedo M; Henríquez DR; Plate L; Chana-Cuevas P; Saquel C; Thielen P; Longo KA; Geddes BJ; Lederkremer GZ; Sharma N; Shenkman M; Naphade S; Sardi SP; Spichiger C; Richter HG; Court FA; Tshilenge KT; Ellerby LM; Wiseman RL; Gonzalez-Billault C; Bergink S; Vidal RL; Hetz C
    Acta Neuropathol; 2020 Nov; 140(5):737-764. PubMed ID: 32642868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration.
    Lu B; Palacino J
    FASEB J; 2013 May; 27(5):1820-9. PubMed ID: 23325320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
    Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
    J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
    Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
    J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.
    Bissonnette S; Vaillancourt M; Hébert SS; Drolet G; Samadi P
    PLoS One; 2013; 8(9):e75099. PubMed ID: 24040390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
    Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
    Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease.
    Wu B; Jiang M; Peng Q; Li G; Hou Z; Milne GL; Mori S; Alonso R; Geisler JG; Duan W
    Exp Neurol; 2017 Jul; 293():83-90. PubMed ID: 28359739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease.
    Masuda N; Peng Q; Li Q; Jiang M; Liang Y; Wang X; Zhao M; Wang W; Ross CA; Duan W
    Neurobiol Dis; 2008 Jun; 30(3):293-302. PubMed ID: 18395459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
    Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
    Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paroxetine retards disease onset and progression in Huntingtin mutant mice.
    Duan W; Guo Z; Jiang H; Ladenheim B; Xu X; Cadet JL; Mattson MP
    Ann Neurol; 2004 Apr; 55(4):590-4. PubMed ID: 15048901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
    Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
    Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
    Jiang M; Peng Q; Liu X; Jin J; Hou Z; Zhang J; Mori S; Ross CA; Ye K; Duan W
    Hum Mol Genet; 2013 Jun; 22(12):2462-70. PubMed ID: 23446639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
    Seo H; Kim W; Isacson O
    Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired basal and running-induced hippocampal neurogenesis coincides with reduced Akt signaling in adult R6/1 HD mice.
    Ransome MI; Hannan AJ
    Mol Cell Neurosci; 2013 May; 54():93-107. PubMed ID: 23384443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
    Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
    Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
    Ho LW; Brown R; Maxwell M; Wyttenbach A; Rubinsztein DC
    J Med Genet; 2001 Jul; 38(7):450-2. PubMed ID: 11432963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.